Product license NPN 80149608 authorizes the following approved health claims for SRI-81 Shatavari:
- Helps manage menopausal symptoms.Helps relieve vasomotor symptoms in perimenopausal women, such as hot flashes and night sweats.
- Helps reduce menopausal symptoms such as mild anxiety, irritability, and fatigue.
- Helps relieve symptoms of menopause to support and maintain overall wellbeing and quality of life in women.
- Helps support healthy sexual arousal and satisfaction in women.
SRI-81 Shatavari was launched at SupplySide Global 2025 in Las Vegas. The ingredient is distributed exclusively in Canada by CK Nutraceuticals, which has a long partnership with Ixoreal Biomed on its flagship KSM-66 ashwagandha.
Ayurvedic traditional use
Dubbed the “Queen of Herbs,” Shatavari (Asparagus racemosus) has a long history in Ayurveda. The herb is reported to contain phytoestrogens, compounds known for their weak estrogen-like effects. Previous studies have found that shatavarins, key phyto-actives in shatavari, may interact with estrogen receptors.
According to a 2024 paper in Bioinformation, “Shatavari is an important Ayurvedic herb that has several bioactive phytoconstituents such as various shatavarins which have high molecular weights and large structures.
“The effects of shatavari are well-known in improving female health conditions. Shatavari is known to manage and improve female reproductive health, managing symptoms of menopause, antioxidant effect, anti-anxiety effect, helps in proper lactation and other female health-related aspects,” wrote scientists from Jawaharlal Nehru Technological University-Hyderabad in India.
SRI-81 Shatavari is standardized to Shatavarin IV as well as total shatavarins and is designed to provide science-backed support for women seeking natural solutions during the menopausal transition.
“The Health Canada approval represents an important milestone for SRI-81 Shatavari and provides Canadian supplement brands with a compliant pathway to formulate innovative women’s health products backed by both clinical research and regulatory approval,” said Colleen Madden, VP Innovation at CK Nutraceuticals.
